
ALK, ROS1 and EGFR next-generation tyrosine kinase inhibitors in advanced non-small-cell lung cancer
Author(s) -
Kinga Winiarczyk,
Aleksandra Piórek,
Maciej Krzakowski
Publication year - 2019
Publication title -
oncology in clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
H-Index - 2
eISSN - 2450-6478
pISSN - 2450-1654
DOI - 10.5603/ocp.2018.0042
Subject(s) - medicine , ros1 , lung cancer , tyrosine kinase , tyrosine kinase inhibitor , pathogenesis , targeted therapy , cancer , oncology , protein tyrosine kinases , cancer research , adenocarcinoma , receptor